Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

1. Di Leo, A.
2. Johnston, S.
3. Lee, K.S.
4. Ciruelos, E.
5. Lønning, P.E.
6. Janni, W.
7. O'Regan, R.
8. Mouret-Reynier, M.-A.
9. Kalev, D.
10. Egle, D.
11. Csőszi, T.
12. Bordonaro, R.
13. Decker, T.
14. Tjan-Heijnen, V.C.G.
15. Blau, S.
16. Schirone, A.
17. Weber, D.
18. El-Hashimy, M.
19. Dharan, B.
20. Sellami, D.
21. Bachelot, T.